Menu

Blog

Page 3583

Jan 5, 2023

The molecules behind metastasis

Posted by in category: biotech/medical

Many cancer cells never leave their original tumors. Some cancer cells evolve the ability to migrate to other tissues, but once there cannot manage to form new tumors, and so remain dormant. The deadliest cancer cells are those that can not only migrate to, but also thrive and multiply in distant tissues.

These metastatic are responsible for most of the deaths associated with cancer. Understanding what enables some cancer cells to metastasize—to spread and form new tumors—is an important goal for researchers, as it will help them develop therapies to prevent or reverse those deadly occurrences.

Past research from Whitehead Institute Member Robert Weinberg and others suggests that cancer cells are best able to form metastatic tumors when the cells are in a particular state called the quasi-mesenchymal (qM) state. New research from Weinberg and Arthur Lambert, once a postdoc in Weinberg’s lab and now an associate director of translational medicine at AstraZeneca, has identified two gene-regulating molecules as important for keeping cancer cells in the qM state.

Jan 5, 2023

A Triple Immunotherapy Regimen for Pancreatic Cancer

Posted by in category: biotech/medical

Immunotherapy, including immune checkpoint inhibitors (ICIs), has changed the landscape of cancer treatment in the last decade. Immunotherapies, treatments targeting a patient’s immune system instead of the cancer itself, work on cancers considered “hot,” indicating that the tumor contains immune cells and factors which favor an anti-tumor immune response. Cancers that respond to immune-based therapies are known as “immunogenic” since the treatment can stimulate the immune response.

On the other hand, “cold” cancers, characterized as “non-immunogenic,” fail to respond to immunotherapies. One cancer understood as refractory to immune-based regimens is pancreatic ductal adenocarcinoma (PDAC), a highly aggressive pancreatic malignancy where less than 10% of patients survive five years past diagnosis. ICIs, including those targeting PD-L1 and CTLA-4 lack the efficacy to impact survival outcomes in PDAC patients significantly. Further, estimates project that by 2030, PDAC will rise to the second-highest cause of cancer-related deaths. Thus, there remains a significant need to develop novel and practical strategies to treat patients with this disease.

Jan 5, 2023

What Are The Odds Of Alien Life? The Drake Equation

Posted by in categories: alien life, chemistry, Elon Musk, information science, mathematics, physics

Commercial Purposes ► [email protected].

What is the Drake Equation? We are talking about The Odds of ALIEN LIFE.
Is there life out there in the Universe?
How are the chances to find Extraterrestrial life?

Continue reading “What Are The Odds Of Alien Life? The Drake Equation” »

Jan 5, 2023

Interstellar Colonization Strategies

Posted by in category: space travel

Go to hhttp://hover.com/isaacarthur and get 10% off any domain name from Hover
extensions for anything you’re passionate about.
As we seek to travel vast distances to claim the galaxy, we will need to develop strategies and methods for voyaging through deep space and reaching strange new worlds.

Visit our Website: http://www.isaacarthur.net.
Join Nebula: https://nebula.tv/isaacarthur.
Support us on Patreon: https://www.patreon.com/IsaacArthur.
Support us on Subscribestar: https://www.subscribestar.com/isaac-arthur.
Facebook Group: https://www.facebook.com/groups/1583992725237264/
Reddit: https://www.reddit.com/r/IsaacArthur/
Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.
SFIA Discord Server: https://discord.gg/53GAShE

Continue reading “Interstellar Colonization Strategies” »

Jan 5, 2023

Rate of scientific breakthroughs slowing over time: Study

Posted by in category: innovation

The rate of ground-breaking scientific discoveries and technological innovation is slowing down despite an ever-growing amount of knowledge, according to an analysis released Wednesday of millions of research papers and patents.

While previous research has shown downturns in individual disciplines, the study is the first that “emphatically, convincingly documents this decline of disruptiveness across all major fields of science and technology,” lead author Michael Park told AFP.

Park, a doctoral student at the University of Minnesota’s Carlson School of Management, called disruptive discoveries those that “break away from existing ideas” and “push the whole scientific field into new territory.”

Jan 5, 2023

This Cancer Vaccine Can Eliminate and Prevent Brain Tumors

Posted by in categories: biotech/medical, neuroscience

It’s an early step forward and needs way more testing. But the potential is high. Cancer vaccines aren’t a new idea. They use the same fundamentals that enable vaccines for infectious pathogens like viruses and bacteria: priming our immune system into recognizing and attacking something that’s harmful to our bodies.

Jan 5, 2023

Nucleophagy delays aging and preserves germline immortality Aging

Posted by in category: life extension

Nuclear morphology changes with aging, but the role of these changes and the underlying mechanisms are not fully understood. The authors find that the nuclear envelope anchor protein ANC-1 in worms, and its counterpart nesprin-1 and nesprin-2 in mammals, promotes the degradation of nuclear components to limit nucleolar size and function in a soma longevity and germline immortality mechanism.

Jan 5, 2023

After Hibernation, Bears Clear P-Tau Aggregates

Posted by in categories: biotech/medical, neuroscience

Series — Clinical Trials on Alzheimer’s Disease (CTAD) 2022: Part 1 of 14: Dare We Say Consensus Achieved: Lecanemab Slows the Disease Part 2 of 14: Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial Part 3 of 14: Two New Stabs at Vaccinating People Against Pathologic Tau Part 4 of 14: Cognitive Tests Taken at Home Are on Par with In-Clinic Assessments Part 5 of 14: In Small Trial, Gene Therapy Spurs ApoE2 Production Part 6 of 14: Donanemab Mops Up Plaque Faster Than Aduhelm Part 7 of 14: Gantenerumab Mystery: How Did It Lose Potency in Phase 3? Part 8 of 14: Could Personalizing Multimodal Interventions Give Them Oomph?

Jan 5, 2023

Why Kids Are “Smarter”: Study Reveals Explanation for Faster Learning

Posted by in categories: education, neuroscience

If you’ve ever thought your children in elementary school were “smarter” than you, or at least quicker at taking up new skills and knowledge, new research published in the journal Current Biology confirms that you were correct. According to the new study, there are differences in the brain messenger GABA between kids and adults, which may explain why kids often seem to be more capable of learning and retaining new information.

“Our results show that children of elementary school age can learn more items within a given period of time than adults, making learning more efficient in children,” said Takeo Watanabe of Brown University.

According to the study, children experienced a rapid increase in GABA during visual training, which lasted even after the training ended. In contrast, GABA concentrations in adults remained constant during training. These findings suggest that children’s brains are more responsive to training, allowing them to quickly and efficiently consolidate new learning.

Jan 5, 2023

South Korea fines Tesla $2.2 million for exaggerating driving range of EVs

Posted by in categories: sustainability, transportation

SEOUL (Reuters) — South Korea’s antitrust regulator said it would impose a 2.85 billion won ($2.2 million) fine on Tesla Inc for failing to tell its customers about the shorter driving range of its electric vehicles (EVs) in low temperatures.

The Korea Fair Trade Commission (KFTC) said that Tesla had exaggerated the “driving ranges of its cars on a single charge, their fuel cost-effectiveness compared to gasoline vehicles as well as the performance of its Superchargers” on its official local website since August 2019 until recently.

The driving range of the U.S. EV manufacturer’s cars plunge in cold weather by up to 50.5% versus how they are advertised online, the KFTC said in a statement on Tuesday.